Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar),ey cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.
A phase 3 clinical trial has started recruiting (November 2009) to use sorafenib for non-responsive thyroid cancer The results were presented at the ASCO 13th Annual Meeting and are the base for FDA approval. The Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The Phase 3 DECISION trial showed significant improvement in progression-free survival but not in overall survival. However, as is known, the side effects were very frequent, specially hand and foot skin reaction.
A phase 3 clinical trial is under way testing the effectiveness of Sorafenib to treat desmoid tumors (also known asaggressive fibromatosis), after positive results in the first two trial stages. Dosage is typically half of that applied for malignant cancers (400 mg vs 800 mg). NCI are sponsoring this trial.
How should this medicine be used?
Sorafenib comes as a tablet to take by mouth. It is usually taken twice a day. Sorafenib is taken without food, 1 hour before or 2 hours after a meal. Take sorafenib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take sorafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Sorafenib is not available in pharmacies. You can only get sorafenib through the mail from a specialty pharmacy. Ask your doctor if you have any questions about receiving your medication.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.